ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning

This ASO perspective reviews the findings of a randomized placebo-controlled, clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma, reported recently by the Checkmate 577 investigators. The use of postoperative immunotherapy represents a significant paradigm shift for managing patients who have had limited evidence-based treatment options after completing neoadjuvant chemoradiation followed by resection for these aggressive malignancies.

Automated summary

This article reviews the findings of a randomized clinical trial evaluating adjuvant nivolumab in esophageal or gastroesophageal junction carcinoma. The study suggests that postoperative immunotherapy represents a significant treatment option for these aggressive malignancies.